Original articleA comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure:: A 12-week, randomized, masked-evaluator multicenter study☆
Section snippets
Setting
This 12-week, randomized, parallel-group, masked-evaluator study conducted at 45 sites in the United States compared the efficacy and safety of once daily administration of three commercially available prostaglandin analogues: latanoprost 0.005%, bimatoprost 0.03%, and travoprost 0.004% ophthalmic solutions. Regulatory authorities at each study site reviewed and approved the protocol in accordance with guidelines for the conduct of clinical research contained in the 1964 Declaration of Helsinki.
Patient disposition and demographics
In all, 514 patients were screened; 1 patient was excluded at the week 2 safety check because of an elevated IOP. Following enrollment at baseline, 411 patients were randomized to three treatment groups: latanoprost (n = 136), bimatoprost (n = 137), and travoprost (n = 138) (Figure 2). One patient in the bimatoprost group received medication but had no postbaseline evaluation and was excluded from ITT analyses. The resulting ITT population comprised 410 patients of whom 172 (42.0%) were male,
Discussion
We believe that this is the first randomized, controlled trial simultaneously comparing the IOP-lowering efficacy and safety of latanoprost, bimatoprost, and travoprost. Over 12 weeks, we found no significant differences in efficacy among the three medications in patients with open-angle glaucoma or ocular hypertension using an ITT analysis; results were supported by findings of per-protocol analyses. At the conclusion of the study, IOP measurements were significantly reduced from baseline for
Appendix
Members of the XLT Study Group: Stacey Ackerman, MD, Willingboro, NJ; Louis Alpern, MD, El Paso, TX; Charles Beischel, MD, Charleston, SC; Richard Bennion, MD, Wenatchee, WA; M. Ellen Berg, MD, Shreveport, LA; Bruce Bodner, MD, Virginia Beach, VA; W. Benton Boone, MD, Inglewood, CA; James Branch, MD, Winston-Salem, NC; Carl Camras, MD, Omaha, NE; Neil Choplin, MD, San Diego, CA; William Christie, MD, Pittsburgh, PA; Lawrence Cooper, MD, San Diego, CA; Douglas Day, MD, Atlanta, GA; Jonathan
References (37)
- et al.
Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics
Am J Ophthalmol
(2001) Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections
Exp Eye Res
(1998)- et al.
Effects of PhXA41, a new prostaglandin F2α analog, on aqueous humor dynamics in human eyes
Ophthalmology
(1993) - et al.
Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function
Surv Ophthalmol
(1997) - et al.
Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morninga comparison with timolol
Ophthalmology
(1995) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucomaa six-month, masked, multicenter trial in the United States
Ophthalmology
(1996)- et al.
A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension
Ophthalmology
(1996) - et al.
Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure
Surv Ophthalmol
(2001) - et al.
Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
Am J Ophthalmol
(2001) - et al.
A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6-Month data
Am J Ophthalmol
(2002)
Efficacy and safety of bimatoprost in patients with elevated intraocular pressurea 30-day comparison with latanoprost
Surv Ophthalmol
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma
Am J Ophthalmol
Bimatoprost and travoprosta review of recent studies of two new glaucoma drugs
Surv Ophthalmol
Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids
Surv Ophthalmol
Prostaglandin analog treatment of glaucoma and ocular hypertension
Ann Pharmacother
Bimatoprosta member of a new class of agents, the prostamides, for glaucoma management
Exp Opin Invest Drugs
Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits
J Ocul Pharmacol Ther
Cited by (428)
One More Time: Generic Solutions are the Same as Branded
2023, Ophthalmology GlaucomaTrends in development and quality assessment of pharmaceutical formulations - F2α analogues in the glaucoma treatment
2023, European Journal of Pharmaceutical SciencesDuration of the hypotensive effect of prostaglandin analogues measured with the water drinking test in glaucoma patients
2022, Archivos de la Sociedad Espanola de OftalmologiaGlaucoma
2022, Comprehensive Pharmacology
- ☆
Research sponsored by Pharmacia Corporation.